Phase III study of gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer with EGFR mutation

Trial Profile

Phase III study of gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer with EGFR mutation

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Results from a meta-analysis of 6 trials showing impact on overall survival in patients with EGFR mutations presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jul 2014 Updated overall survival results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2012 Updated overall survival results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top